|2021 Centre for Medicines Research (CMR) Pharmaceutical R&D Factbook from Clarivate Finds Drug Approvals at a 10-year High Despite the Challenges of COVID-19|
|By: PR Newswire Association LLC. - 15 Sep 2021||Back to overview list
LONDON, Sept. 15, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of the 2021 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook. The 2021 CMR R&D Factbook centers on how the pandemic may have impacted drug launches, development times and approvals. This year's report finds that the pharmaceutical industry has responded well to the challenges of COVID-19. In fact, 2020 saw a 10-year high of new molecular entities (NMEs) launched into the world market.
The Centre for Medicines Research, a wholly owned subsidiary of Clarivate, has released the 2021 Centre for Medicines Research (CMR) Pharmaceutical R&D Factbook to help pharma and biotech companies benchmark their drug development efforts against industry leaders. The new Factbook provides insights on R&D expenditures, cycle times, pipeline growth and more to allow companies to access and analyze success rates and key activities from drug discovery through commercialization. These insights can ultimately help them establish reliable internal KPIs throughout the entire drug development lifecycle.
Mukhtar Ahmed, President, Science Group, Clarivate, said: "We are all waiting to see the long-term impacts the pandemic will have on the biopharma industry. Preliminary data indicate that drug launches, development times and approvals were not impacted in 2020. It takes an average of 10 years to develop and launch a drug. We anticipate the impact of COVID-19 will be seen even more clearly through the data CMR collects over the next decade, with next year's CMR Factbook set to show the immediate impacts of the pandemic on drug development."
CMR International has published the Pharmaceutical R&D Factbook, an annual report designed to equip the pharmaceutical clinical sector with a reliable quotable source of key reference metrics and an insight into current industry trends since 2006. This analysis was derived from proprietary, anonymized data gathered from more than 25 leading Pharma and Biotech companies of all sizes and therapy areas in order to aid the industry in making more strategic decisions and bringing life-saving therapies to patients as quickly and safely as possible.
To learn more about the 2021 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook, visit here.
CMR International is the world's most reputable source of industry metrics and trends analysis. Experience, independence and integrity paired with a dedication to providing industry-leading data, insights and opinions, make CMR International the partner of choice for the world's major pharmaceutical innovators. CMR International is distinguished by its unique ability to collect, validate and analyze industry-wide proprietary R&D performance metrics, using a proven and secure process. This capability enables CMR International to provide partners with readily accessible information designed to maximize the effectiveness and efficiency of their R&D operations. As a result, CMR International is the world's most authoritative source of pharmaceutical R&D performance metrics, facts and trends.
To learn more about CMR International visit https://clarivate.com/cortellis/solutions/benchmarking-services/.
1 "2021 CMR International Pharmaceutical R&D Factbook" September 2021. Source: The Centre for Medicines Research
2 "2021 CMR International Pharmaceutical R&D Factbook" September 2021. Source: The Centre for Medicines Research
3 The list of the most popular targets was determined by evaluating individual companies filing patent applications on novel small molecules with therapeutic activity where no previous patents from the organization claiming novel small molecules against the same target already exist.
4 The top 30 innovative companies are defined by the number of patents filed on novel targets as sourced from data found in Cortellis Competitive Intelligence.
SOURCE Clarivate Plc
Copyright 2021 PR Newswire Association LLC.
|Back to overview list|